BioAtla (BCAB) Non-Current Assets (2020 - 2026)
BioAtla (BCAB) posted quarterly Non-Current Assets of -$3.1 million for Q1 2026, down 510.76% year-over-year from $753000.0 in Q1 2025, and up 17.03% quarter-over-quarter from -$3.7 million in Q4 2025.
BioAtla (BCAB) Non-Current Assets (2020 - 2026) Analysis & Trends
BioAtla's Non-Current Assets history runs 7 years deep, the most recent figure standing at -$3.1 million for Q1 2026.
- In Q1 2026, Non-Current Assets fell 510.76% year-over-year to -$3.1 million; the TTM figure through Mar 2026 stood at $5.9 million (up 3.06% YoY), while the FY2025 annual figure was -$3.7 million, down 413.28% from the prior year.
- Non-Current Assets for Q1 2026 stood at -$3.1 million, up from -$3.7 million in the prior quarter.
- The five-year high for Non-Current Assets was $6.6 million in Q1 2022, with the low at -$3.7 million in Q4 2025.
- The 5-year median for Non-Current Assets is $3.9 million (2023), against an average of $3.2 million.
- The sharpest annual moves came in 2025 and 2026: Non-Current Assets soared 273.76% in 2025, then slumped 510.76% in 2026.
- BioAtla's Non-Current Assets stood at $5.3 million in 2022, then plunged by 38.7% to $3.3 million in 2023, then sank by 63.41% to $1.2 million in 2024, then plunged by 413.28% to -$3.7 million in 2025, then gained by 17.03% to -$3.1 million in 2026.
- Business Quant data shows BCAB's Non-Current Assets at -$3.1 million in Q1 2026, -$3.7 million in Q4 2025, and $6.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 938.60 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 468.65 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 18.06 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 6.80 Bn |
| 10 | BioAtla | 5.28 Mn | 5.28 Mn | - | -2.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.98 Mn |
| Mar 31, 2026 | -3.09 Mn |
| Dec 31, 2025 | -3.73 Mn |
| Sep 30, 2025 | 6.24 Mn |
| Jun 30, 2025 | 6.52 Mn |
| Mar 31, 2025 | 753,000.00 |
| Dec 31, 2024 | 1.19 Mn |
| Sep 30, 2024 | 1.67 Mn |
| Jun 30, 2024 | 2.15 Mn |
| Mar 31, 2024 | 2.77 Mn |
| Dec 31, 2023 | 3.25 Mn |
| Sep 30, 2023 | 3.85 Mn |
| Jun 30, 2023 | 4.33 Mn |
| Mar 31, 2023 | 4.84 Mn |
| Dec 31, 2022 | 5.31 Mn |
| Sep 30, 2022 | 5.80 Mn |
| Jun 30, 2022 | 6.30 Mn |
| Mar 31, 2022 | 6.63 Mn |
| Dec 31, 2021 | 7.13 Mn |
| Sep 30, 2021 | 4.06 Mn |